Hemophilia B Leyden is an X chromosome-linked bleeding disorder characterized by an altered developmental expression of blood coagulation factor IX. This form of hemophilia B has been found to be associated with a variety of single point mutations in the factor IX promoter region. We now describe a novel point mutation, T+G at position -21, in two related patients with the hemophilia B Leyden phenotype. This mutation lies within the factor IX promoter region ( -40 to -9) that contains overlapping binding sites for hepatocyte nuclear factor 4 (HNF-4) and androgen receptor. Transient transfection assays in HepG2 cells show that the -21 mutation causes a significant reduction in factor IX promoter activity. Gel mobility shift assays and transient cotransfection experiments revealed that the HNF-4-binding site but not the androgenresponsive element is disrupted by the -21 mutation. A comparison of the -21 mutation with the previously described -2 0 T+A mutation (associated with the hemophilia B Leyden phenotype) and -26 G+C mutation (as-EMOPHILIA B is an X-linked bleeding disorder. It H results from a deficiency of clotting factor IX (fIX), a vitamin K-dependent glycoprotein normally present in plasma and an essential component of the clotting cascade.' The majority of mutations causing hemophilia B has been found in the coding sequence of the fIX gene, whereas all mutations identified in a subgroup of patients with hemophilia B (hemophilia B Leyden) were detected in the fIX promoter sequence (at -20, -6, -5, +6, t-8, and + 13*).
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The characteristic aspect of hemophilia B Leyden is the altered developmental expression of flX. 334 In the patients, plasma fIX levels are less than 1% of normal during childhood, but after puberty, they gradually rise to a maximum of 70% of normal.* Apparently, in these patients, the fI X gene only becomes transcriptionally active after puberty; probably under the influence of te~tosterone.~
The positions of the mutations associated with hemophilia B Leyden suggest that they disrupt binding sites for transcription factors that are crucial for constitutive fIX transcription. The observation that the mutations at -20 T+A and + 13 A+G interfere with the binding of HNF-45 and C/EBP,6 respectively, further supports this view.
A recent publication reports that the fI X promoter contains a consensus androgen-responsive element (-36 to -22) that partially overlaps with the consensus HNF-4-binding site (-27 to -1 5).7 Both the androgen-responsive element and the HNF-4-binding site were simultaneously disrupted by a -26 G-tC mutation in the fl X promoter.
This mutation was detected in a patient who has suffered from severe hemophilia throughout
In this report, we describe a novel point mutation, T+G The results indicate that the disruption of the HNF-4-binding site by the -2 1 T+G mutation is the cause of the bleeding disorder in these t w o patients. This study adds further support for the notion that the recovery from hemophilia at puberty may not only be related to an intact androgen-responsive element but also to the degree of disruption of the HNF-4-binding site.
0 1993 by The American Society of Hematology.
binding site but not the androgen-responsive element is disrupted by the -2 1 mutation.
PATIENTS, MATERIALS, AND METHODS
The family studied is of Belgium origin (Fig IA) . Patient 111-5 had regular spontaneous hemarthroses at least once weekly, usually in his ankles and right elbow and occasionally in his knees till the age of 15 years. From that age onward, spontaneous hemarthroses no longer occurred, and the patient only needed transfusions after accidents or prophylactically before minor surgery. Patient 111-8 had very frequent, recurrent spontaneous hemarthroses as a child, especially in the right elbow. At least weekly transfusions were needed till the age of 14. Thereafter, the frequency of spontaneous hemarthroses diminished, and at the age of 18, the spontaneous bleeding tendency disappeared.
Blood samples, collected in 0.1 volume of 0.1 1 mol/L sodium citrate, were obtained from the patients (111-5 and 111-8) and the family members (11-3,11-4, and 111-9). Plasma was obtained by cen- 3' and S'"ACGCGffGCATAACCTTTGC'" 3'. Amplified DNA obtained from two separate amplification reactions was purified by agarose gel electrophoresis and sequenced using the Sanger direct sequencingstrategy. Sequencedata were obtained by sequenceanalysis of both the sense and antisense strands of DNA. The analysis was limited to determining the nucleotide sequence of the flX promoter region between nucleotide -I92 and +40. The CAT activity of each construct. which was normalized for 8-galactosidase activity. was determined in three independent transfection experiments. Shown is the average normalized CAT activity of three experiments.
Patients
G d tnohi/ity shi/i a.s.saj: The analysis of protein-DNA complexes by mobility shin assays'and the preparation ofcrude nuclear extracts from rat livers and H e 6 2 cells were as described previously.'."." Labeled oligonucleotides containing the wild-type or -21 mutated flX promoter region (-40 to -9: Table I ) were incubated with nuclear extracts from rat liver. HepG2 cells. or in vitro translated HNF-4" either in the ahsence or presence ofcompetitor DNA. Bacterially expressed androgen receptor-protein A fusion protein (a gin from Dr P. De Vos") was used in mobility shin assays of androgen-responsive element containing oligonucleotides (oligo "w". m-2 I, m-20, m-26 and ARE: Table I ). These experiments were performed exactly as described by De Vos et ai."
For competition experiments. increasing amounts of doublestranded oligonucleotide competitors (Table I ) were added lo a constant amount of nuclear extract and "P-labeled probe DNA. Relative amounts of protein-DNA complexes were determined either by densitometric analysis (LKR Ultroscan XL dcnsitometer. Pharmacia, Uppsala. Sweden) of autoradiographs or by counting For personal use only. on October 22, 2017. by guest www.bloodjournal.org From the amount of radioactivity (protein bound and free probe) from the dried gels on the Phosphor Imager (Molecular Dynamics, Sunnyvale, CA) using the Image Quant analysis system. Shown is the average of three experiments.
RESULTS
The factor IX coagulant activity levels (fIX:C) in the two patients with hemophilia B Leyden (111-5 and 111-8) were measured up to the age of 19 and 22 years, respectively ( Fig  1B) . The patients had a clinical history compatible with severe hemophilia B in the prepuberty years (flX:C levels below l % of normal). One of the patients needed prophylactic treatment for frequent hemorrhages. After onset of puberty, the f€X:C levels gradually rose to 12% to 14% and are still rising. With the rise of fIX:C levels, the spontaneous bleeding tendency disappeared. In a recent blood sample of these two hemophiliacs, factor IX antigen was found to be -lo%, with factor IX antigen/activity ratios of 0.96 and 0.7 1, respectively (indicating the synthesis of fully active factor IX molecules).
A variety of single point mutations in the putative fIX promoter region has been associated with hemophilia B Leyden. Using the strategy of PCR amplification and the Sanger direct sequencing analysis, we determined the sequence of the fIX promoter region of these two patients with hemophilia B Leyden (Fig IC, 111-5 and 111-8) . A novel point mutation, T+G at position -2 1, of the fl X gene was detected. This mutation, in addition to a normal allele, was also present in maternal DNA (11-3 and 11-4) and DNA prepared from the sister (111-9) of patient 111-8, thus confirming their carrier status.
To determine whether the -2 1 T-tG mutation impairs transcription from the fIX promoter, we analyzed the transcriptional activity of the wild-type and -2 1 mutated promoters. The fI X promoter-CAT constructs containing wild-type and -2 1 T+G mutated fragments (extending from -192 to +38) were tested for expression in transiently transfected HepG2 and HeLa cells. In agreement with previous observations, the wild-type promoter of the human fix gene was capable of directing CAT transcription in HepG2 cells but not in HeLa cells (Fig 2) . When the transfections in HepG2 were carried out with the -21 T+G mutated construct (-192(-21T+G)CATOO.I), only a background level of CAT activity was found. Similar experiments as described for the -21 mutation were previously The sequence and location of the top strand of the oligonucleotides used in competition binding assays are given. Mutated nucleotides are indicated by lower case letters.
done for the -20 T-A and -26 G+C mutated fI X promoters. Like the -21 mutation, they also produced only background levels of CAT activity in HepG2 cells (Fig 2A) . 5 Because the T+G mutation at -21 lies within a region that contains a HNF-4-binding site and an overlapping androgen-responsive element, we tested whether this mutation disrupts either of them. Oligonucleotides containing the -40 to -9 region of the fIX promoter (wild type: oligo "wt" and -2 1 T+G mutated: oligo m-21) were used in gel mobility shift assays (Table 1) . HNF-4 protein, either from HepG2 cells (Fig 3A, lanes 1 and 3) or translated in vitro from HNF-4 cDNA (lane 8), bound the labeled oligo "wt" very well. When the experiments were carried out with labeled oligo m-2 1, reduced binding of HNF-4 to -2 1 mutated site was found (lane 2). The labeled HNF-4-DNA complex was competed effectively by 40-fold molar excess of unlabeled oligo "wt" (lanes 4 and 9) and to a lesser extent by oligo m-21 (lanes 5 and IO). To confirm that indeed HNF-4 binding is involved, we incubated the mobility shift reaction mixtures with specific antibodies to HNF-4." This resulted in a "supershift" of the complex (lane 6). The addition of anti-NF-1 antibody (lane 7, negative control16) had no effect. Additional competition experiments were performed with increasing amounts of unlabeled competitor DNA (oligo "wt", m-2 1, m-20 or m-26; Table 1 ) added to a constant amount of rat liver nuclear extract and labeled oligo "wt" (Fig 3B) . The experiments were repeated three times. Both the -21 mutation and the -20 mutation disrupt the HNF-4-binding site to a similar level (-I6 times more mutant DNA than wild-type DNA was needed to reduce the formation of labeled protein-DNA complex by 50%). The -26 mutated oligonucleotide (m-26) competed only marginally for HNF-4 binding. Similar observations were made with HepG2 nuclear extracts (data not shown). These results indicate that the mutation at -21 interferes with HNF-4 binding to the fI X promoter. Moreover, although the -21 mutation and the -20 mutation partially reduce HNF-4 binding, the -26 mutation seems to completely disrupt the HNF-4-binding site.
To determine whether the androgen-responsive element was also disrupted by the -2 1 mutation, we performed gel mobility shift assays with a recombinant androgen receptor-protein A fusion protein. 15 When the experiments were carried out with labeled oligo "wt" as probe, only a small fraction ofthe probe was retarded (Fig 4A, lanes 1 and 2) . In contrast, the fusion protein bound very well to a probe containing the well-characterized androgen-responsive element from the rat prostatic binding protein gene (oligo ARE, lanes 3 and 4). Therefore, in an attempt to establish a difference in binding of the fusion protein to the wild-type and -2 1 mutated fl X promoter region, we performed competition experiments with oligo ARE as probe and increasing concentrations of unlabeled oligo "wt" and oligo m-2 1 as competitors (Fig 4B) . Compared with the competition with oligo ARE, large amounts (300-to 400-fold mol/L excess) of unlabeled oligo "wt" and oligo m-2 I were required to reduce the formation of labeled protein DNA complex by 50% (Fig 4B,C) . There was no significant difference in competition for fusion protein binding between oligo "wt" and oligo m-2 1. When the experiments were carried out with unlabeled oligo m-20 as competitor. similar results were COUP-TF-binding sequence (COUP). These results indiobtained (Fig 4C) . The affinity of the fusion protein for cate that the HNF-4-binding site but not the androgen-reoligo m-26 was lower since a twofold higher concentration sponsive element is disrupted by the -21 T+G mutation. of DNA was needed to reduce the formation of labeled pro-
The functional consequence of the reduction in HNF-4 tein DNA complex by 50%. No competition was observed binding to the -21 mutated flX region was analyzed by with excess unlabeled oligonucleotide containing the transient cotransfection experiments in H e 6 2 and HeLa
For For personal use only. on October 22, 2017. by guest www.bloodjournal.org From cells. In these experiments, an expression vector for HNF-4 (pLEN4S") was cotransfected with the reporter constructs described above. The results presented in Fig 2A, 
DISCUSSION
A T+G base change at position -2 I was detected in the fI X promoter region of two related patients with the hemophilia B Leyden phenotype. The mothers ofthe patients also carried the defective allele suggesting that the original mutation has occurred in one of their parents or other forebears.
The T+G mutation at -2 I in both patients is associated with severe bleeding symptoms and plasma fIX levels below 1% of normal during childhood. The severity of the fIX deficiency in these two patients is similar to those observed in the patients with mutations at position -20. Interestingly, the residues at -22, -21, and -20 (all thymine residues) are conserved in various mammalian species (ie, human, macaque, dog, rat, and mouseI7). It seems that the residues at -2 1 and -20 are critical for transcription initiation.
The causal relationship between the -21 T+G base change and the hemophilia B Leyden phenotype was demonstrated by transient transfection analysis and in vitro binding studies. The mutation, which lies within overlapping binding sites for androgen receptor and HNF-4 in the fIX promoter, causes a significant reduction in promoter activity. We showed that the T+G mutation at -2 1 interferes with the binding of HNF-4 to its recognition site (between -34 and -10). Moreover, we show that although HNF-4 transactivates the wild-type fIX promoter quite well, it could activate the -21 T+G mutated promoter only to a limited extent. The data presented here indicate that the disruption of the HNF-4-binding site by the -21 T-G mutation is the cause of the severely impaired (hepatic) flX gene expression in these patients during childhood.
These results add further support for the notion that HNF-4 plays a dominant role in controlling fl X gene expression in normal individuals. In fact, the observation that fIX promoter constructs are very efficiently activated by HNF-4 in the nonhepatic HeLa cells suggest that HNF-4 is the major determinant of the liver-specific production of BX.
It was recently reported that the fIX promoter contains a functional androgen-responsive element between -40 and -9.7 These studies demonstrated that four copies of the wild-type fIX promoter region (-42 to -17) confer androgen responsiveness to a herpes simplex thymidine kinase (tk) promoter in a heterologous system. When the -26 G+C mutation was present no transactivation was observed, whereas the -20 T-A mutation did not affect transactivation in HeLa cells. When we tested this candidate androgen-responsive element in gel mobility shift assays, the binding affinity of the androgen receptor (ie, recombinant androgen receptor-protein A fusion protein) for this site was rather low when compared with the androgen-responsive element from the rat prostatic binding protein gene. Furthermore, transient cotransfection experiments with several different androgen receptor coding plasmids in HepG2 cells showed that this potential androgen responsive element in the fIX promoter responded only poorly to the activation by androgen^.^,^* Although such transactivation experiments may not reflect the in vivo situation, this marginal response to androgens is not comparable with the significant increase in flX expression in patients with hemophilia B Leyden after puberty.
Assuming that the putative fIX androgen-responsive element is functional in the fIX promoter, it is interesting to note that the -26 mutation causes only a minor difference in binding affinity of the androgen receptor-protein A fusion protein. The fact that this mutation not only disrupts the androgen-responsive element but also completely blocks HNF-4 binding suggests a synergistic interaction between androgen receptor and HNF-4. The observation that neither of the hemophilia B Leyden-like mutations at -2 1 and at -20 completely eliminates HNF-4 binding and transactivation suggests that remnant HNF-4 binding is required for the androgen-mediated response after puberty. Both androgen receptor and HNF-4 are members ofthe steroid hormone receptor superfamily, a group of ligand-dependent transcription factors that possess a high degree of similarity in their DNA-binding domains. It is therefore possible that HNF-4 forms heterodimers with the androgen receptor, as has been seen for the thyroid hormone receptors and the retinoic acid receptor^.'^^*^
